Mirum Pharmaceuticals (MIRM) Income towards Parent Company (2019 - 2026)

Mirum Pharmaceuticals' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$790.2 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 5283.63% year-over-year to -$790.2 million; the TTM figure through Mar 2026 stood at -$798.8 million (down 932.9% YoY), while the FY2025 annual figure was -$23.4 million, up 73.43% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$790.2 million, down from -$5.7 million in the prior quarter.
• The five-year high for Income towards Parent Company was $2.9 million in Q3 2025, with the low at -$790.2 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$25.3 million (2024), against an average of -$70.6 million.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company soared 120.41% in 2025, then plunged 5283.63% in 2026.
• Mirum Pharmaceuticals' Income towards Parent Company stood at -$36.4 million in 2022, then grew by 2.12% to -$35.7 million in 2023, then jumped by 33.28% to -$23.8 million in 2024, then surged by 75.91% to -$5.7 million in 2025, then tumbled by 13689.79% to -$790.2 million in 2026.
• Business Quant data shows MIRM's Income towards Parent Company at -$790.2 million in Q1 2026, -$5.7 million in Q4 2025, and $2.9 million in Q3 2025.